Clinical Trial Update: Intravitreal Ranibizumab (Lucentis®) in the Treatment of Non-leaking Macular Cysts in Retinal Dystrophy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating intravitreal ranibizumab (Lucentis) for non-leaking macular cysts in retinal dystrophy has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Retinal Dystrophy

Drugs mentioned

• Lucentis (ranibizumab)

Snippet

Sponsor: Sultan Qaboos University | Conditions: Retinal Dystrophies | Phase 2 | Status: COMPLETED